Last reviewed · How we verify
tranexamic acid Oral-Short Arm
Tranexamic acid inhibits the conversion of plasminogen to plasmin, thereby reducing fibrinolysis and promoting blood clot stability.
Tranexamic acid inhibits the conversion of plasminogen to plasmin, thereby reducing fibrinolysis and promoting blood clot stability. Used for Reduction of blood loss in patients undergoing surgical procedures, Treatment of heavy menstrual bleeding, Prevention and treatment of bleeding in hemophilia patients.
At a glance
| Generic name | tranexamic acid Oral-Short Arm |
|---|---|
| Sponsor | Rush University Medical Center |
| Drug class | Antifibrinolytic agent |
| Target | Plasminogen / Plasmin |
| Modality | Small molecule |
| Therapeutic area | Hematology |
| Phase | FDA-approved |
Mechanism of action
Tranexamic acid is an antifibrinolytic agent that competitively inhibits plasminogen activation and plasmin activity. By reducing the breakdown of fibrin clots, it helps maintain hemostasis and reduce bleeding. This mechanism makes it useful in conditions characterized by excessive fibrinolysis or bleeding.
Approved indications
- Reduction of blood loss in patients undergoing surgical procedures
- Treatment of heavy menstrual bleeding
- Prevention and treatment of bleeding in hemophilia patients
Common side effects
- Nausea
- Vomiting
- Diarrhea
- Thrombotic events (rare)
Key clinical trials
- Oral Tranexamic Acid After Total Knee Arthroplasty (PHASE4)
- Trial to Compare Femoral Nerve Block With Local Anaesthetic Injection for Post-operative Pain After Knee Replacement. (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- tranexamic acid Oral-Short Arm CI brief — competitive landscape report
- tranexamic acid Oral-Short Arm updates RSS · CI watch RSS
- Rush University Medical Center portfolio CI